Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zymeworks Inc. announced FDA clearance for ZW191, a novel FR⍺-targeted ADC for difficult-to-treat cancers, highlighting its unique antibody-linker stability and payload potency. ZW191 targets ovarian, gynecological cancers, and NSCLC, with clinical studies expected in 2024. Zymeworks is advancing a pipeline of ADCs and multispecific antibodies, including zanidatamab for HER2-positive BTC, aiming to address unmet medical needs.
Reference News
Zymeworks Inc. announced FDA clearance for ZW191, a novel FR⍺-targeted ADC for difficult-to-treat cancers, highlighting its unique antibody-linker stability and payload potency. ZW191 targets ovarian, gynecological cancers, and NSCLC, with clinical studies expected in 2024. Zymeworks is advancing a pipeline of ADCs and multispecific antibodies, including zanidatamab for HER2-positive BTC, aiming to address unmet medical needs.